Ligand Pharmaceuticals Inc

LGNZZ

Exchange: OTC
Industry: Pharmaceutical Preparations
SEC CIK: 0000886163

SEC filings (opens in a new tab)

In the last 90 days, Ligand Pharmaceuticals Inc insiders filed 0 open-market purchases and 8 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesLGND LGNDZ LGNXZ LGNYZ

Key figures

Market capClose on Nov 11, 2026: $6.34B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $17.0M in total: 8
13F holdersQ2 2026: 0
13F valueReported value at the end of Q2 2026: $0
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $268.1M; +60.4% year over year
Net income, FY2025: $124.5M; No comparable prior period
Free cash flow, FY2025: $48.9M; −48.6% year over year
Revenue, Q3 FY2026: $78.7M; −31.8% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Jul 31, 2026.

Short interest: 153; Shares sold short
Change: 0; 0.0% vs. previous
Days to cover: 9.00; At average daily volume

Superinvestors holding LGNZZ, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding LGNZZ at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Ligand Pharmaceuticals Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 6, 2026 (view filing)5:41 PM ET	Nov 4	2 days	Aryeh JasonDirector	SSale	−282	$319.99	−$90.2K	−0.3%108.5K after
Nov 4, 2026 (view filing)4:23 PM ET	Nov 2	2 days	Reardon AndrewCLO & Secretary	SSale	−5.00K	$313.22	−$1.57M	−13.6%31.9K after	13 lots10b5-1
Nov 3, 2026 (view filing)7:39 PM ET	Oct 30-Nov 2	4 days	Aryeh JasonDirector	SSale	−2.11K	$320.30	−$676.2K	−1.9%108.8K after	6 lots
Oct 6, 2026 (view filing)4:35 PM ET	Oct 2	4 days	Reardon AndrewCLO & Secretary	SSale	−5.00K	$304.07	−$1.52M	−13.6%31.9K after	6 lots10b5-1
Sep 14, 2026 (view filing)4:59 PM ET	Sep 10	4 days	Zimmermann MartineDirector	SSale	−1.20K	$285.00	−$342.0K	−23.5%3.90K after
Sep 8, 2026 (view filing)6:34 PM ET	Sep 3	5 days	Reardon AndrewCLO & Secretary	SSale	−5.00K	$286.09	−$1.43M	−12.0%36.5K after	5 lots10b5-1
Aug 14, 2026 (view filing)5:05 PM ET	Aug 12	2 days	Espinoza OctavioChief Financial Officer	SSale	−31.6K	$292.07	−$9.24M	−53.3%27.7K after	10b5-1
Aug 14, 2026 (view filing)5:04 PM ET	Aug 12	2 days	Haas JasonDirector	SSale	−7.14K	$292.81	−$2.09M	−64.2%3.98K after
Aug 4, 2026 (view filing)6:42 PM ET	Aug 3	1 day	Reardon AndrewCLO & Secretary	SSale	−5.00K	$288.99	−$1.44M	−10.7%41.5K after	10 lots10b5-1
Jul 6, 2026 (view filing)5:11 PM ET	Jul 1	5 days	Reardon AndrewCLO & Secretary	SSale	−5.00K	$313.28	−$1.57M	−10.7%41.5K after	8 lots10b5-1

Top 10 13F holders, Q2 2026

View all

The largest institutional positions in Ligand Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.

No institution reported holding LGNZZ in 13F filings for Q2 2026.

Politician trades

All politician trades in LGNZZ

2 members of Congress reported 8 trades in Ligand Pharmaceuticals Inc since 2020. Newest filings:

Latest politician trades in LGNZZ
Filed	Politician	Type	Amount
Jun 8, 2026	Gilbert Ray Cisneros, Jr. House · CA	Buy	$1K-$15K
Apr 7, 2026	Gilbert Ray Cisneros, Jr. House · CA	Buy	$1K-$15K
Feb 13, 2026	Gilbert Ray Cisneros, Jr. House · CA	Buy	$1K-$15K
Feb 13, 2026	Gilbert Ray Cisneros, Jr. House · CA	Buy	$1K-$15K
Dec 3, 2020	Katherine M. Clark House · MA	Sell	$1K-$15K

Gilbert Ray Cisneros, Jr.
House · CA · Jun 8, 2026
Buy$1K-$15K
Gilbert Ray Cisneros, Jr.
House · CA · Apr 7, 2026
Buy$1K-$15K
Gilbert Ray Cisneros, Jr.
House · CA · Feb 13, 2026
Buy$1K-$15K
Gilbert Ray Cisneros, Jr.
House · CA · Feb 13, 2026
Buy$1K-$15K
Katherine M. Clark
House · MA · Dec 3, 2020
Sell$1K-$15K